A Dual Electrospray/Photoionization Source

在第二阶段，我们提出了一个实验计划，将导致商业质量 电喷雾/光电离（ES/PI）源。我们计划：（i）优化和建立一个预商业 用于商业质谱仪的原型ES/PI源，以及（ii）开发和 展示了突出ES/PI源独特优势的关键应用， 第一阶段的项目得到满足，并建立了一个原型ES/PI，并在Micromass LCT和 Agilent MSD质谱仪。自第一阶段以来，Syagen进行了额外的测试， 将一个新的源适配到沃茨ZQ。测量ES/PI性能作为流量的函数 速率、加热、PI位置和ES电离（ESI）电压。测试是使用各种 未被ESI有效电离的化合物（例如，类固醇、酚类、醛类等）。PI电离这些 化合物有效。对药物和蛋白质混合物进行了进一步的测试，以检查 同时分析两类化合物的潜力。的意义和重要性 这个工作很高。开发新的电离源用于生命科学研究是一个主要的推动力， 2002年诺贝尔奖的ESI和激光质谱分析 解吸/电离（例如，MALDI）。这项工作将大大扩展 ESI的能力使开发新的先进方法成为可能， 高通量分析。商业MS供应商已经对此技术感兴趣。如果 我们在第二阶段的工作是成功的，我们有信心找到一个商业化的合作伙伴， ES/PI来源

In Phase II we propose an experimental plan that will lead to a commercial quality electrospray/photoionization (ES/PI) source. We plan to: (i) optimize and build a pre-commercial prototype ES/PI source for use on commercial mass spectrometers, and (ii) develop and demonstrate key applications that highlight the unique benefits of the ES/PI source, The goals of the Phase I project were met and a prototype ES/PI was built and tested on a Micromass LCT and an Agilent MSD mass spectrometer. Since Phase I, Syagen has performed additional tests, and has adapted a new source to a Waters ZQ. The ES/PI performance was measured as a function of flow rate, heating, PI position, and ES ionization (ESI) voltage. Tests were conducted using a variety of compounds not ionized efficiently by ESI (e.g., steroids, phenols, aldehydes, etc.). PI ionized these compounds efficiently. Further tests were performed on drug and protein mixtures to examine the potential to analyze both classes of compounds simultaneously. The significance and importance of this work is high. Developing new ionization sources for life science research is a major thrust in mass spectrometry as witnessed by the awarding of the 2002 Nobel Prize for ESI and laser desorption/ionization (e.g., MALDI) of biological molecules. This proposed work will greatly expand the capabilities of ESI making possible the development of new advanced methods for high-throughput analysis. There is already interest in this technology by commercial MS vendors. If we are successful with the Phase II work, we are confident of finding a commercialization partner for the ES/PI source.